Developments in the therapeutic applications of bisphosphonates

被引:42
作者
Brown, DL [1 ]
Robbins, R [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Div Endocrinol & Metab, New York, NY 10021 USA
关键词
D O I
10.1177/00912709922008272
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The authors review the structural, pharmacologic, and clinical aspects of bisphosphonates, a class of drugs currently used to treat several disorders of bone and calcium metabolism. Pertinent literature on the bisphosphonates was reviewed with the help of a MEDLINE search and several bibliographies, including published clinical trials, monographs, and review articles. The bisphosphonates are analogs of pyrophosphate that, when given orally or intravenously, bind avidly to exposed bone mineral and disrupt bone turnover. These agents comprise three groups or generations, based an their potency and chemical structures. All three generations are effective in treating hypercalcemia, Paget's disease of bone, osteoporosis, and other disorders of accelerated bone turnover. The third-generation agents have the greatest potency and offer the promise of a convenient way to suppress or prevent osseous metastasis in patients with certain malignancies. As a group, these agents are well tolerated and, when administered correctly, rarely cause toxicity. The bisphosphonates are safe and effective agents for the treatment of disorders of accelerated bane turnover. (C) 1999 the American College of Clinical Pharmacology.
引用
收藏
页码:651 / 660
页数:10
相关论文
共 57 条
  • [51] Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone
    Siris, E
    Weinstein, RS
    Altman, R
    Conte, JM
    Favus, M
    Lombardi, A
    Lyles, K
    McIlwain, H
    Murphy, WA
    Reda, C
    Rude, R
    Seton, M
    Tiegs, R
    Thompson, D
    Tucci, JR
    Yates, AJ
    Zimering, M
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) : 961 - 967
  • [52] Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study
    Siris, ES
    Chines, AA
    Altman, RD
    Brown, JP
    Johnston, CC
    Lang, R
    Mcclung, MR
    Mallette, LE
    Miller, PD
    Ryan, WG
    Singer, FR
    Tucci, JR
    Eusebio, RA
    Bekker, PJ
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (06) : 1032 - 1038
  • [53] EFFECT OF INTERMITTENT CYCLICAL ETIDRONATE THERAPY ON BONE MASS AND FRACTURE RATE IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
    STORM, T
    THAMSBORG, G
    STEINICHE, T
    GENANT, HK
    SORENSEN, OH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (18) : 1265 - 1271
  • [54] CYCLICAL ETIDRONATE REVERSES BONE LOSS OF THE SPINE AND PROXIMAL FEMUR IN PATIENTS WITH ESTABLISHED CORTICOSTEROID-INDUCED OSTEOPOROSIS
    STRUYS, A
    SNELDER, AA
    MULDER, H
    [J]. AMERICAN JOURNAL OF MEDICINE, 1995, 99 (03) : 235 - 242
  • [55] THIEBAUD D, 1988, AM J MED, V85, P207
  • [56] Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?
    vanHoltenVerzantvoort, ATM
    Hermans, J
    Beex, LVAM
    Blijham, G
    Cleton, FJ
    vanEckSmit, BCF
    Sleeboom, HP
    Papapoulos, SE
    [J]. EUROPEAN JOURNAL OF CANCER, 1996, 32A (03) : 450 - 454
  • [57] INTERMITTENT CYCLICAL ETIDRONATE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
    WATTS, NB
    HARRIS, ST
    GENANT, HK
    WASNICH, RD
    MILLER, PD
    JACKSON, RD
    LICATA, AA
    ROSS, P
    WOODSON, GC
    YANOVER, MJ
    MYSIW, WJ
    KOHSE, L
    RAO, MB
    STEIGER, P
    RICHMOND, B
    CHESNUT, CH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (02) : 73 - 79